You searched for "antibiotics"
ENT leadership
Challenges The first challenge is to agree what we mean by the term leadership because there are many different ways in which the term is used. What is, however, a consensus is that the key distinction between leadership and management...Andreas Wagner: ESPO 2025 keynote speaker
The keynote speaker for ESPO 2025 in Stuttgart is renowned evolutionary biologist and author Professor Andreas Wagner, from Zurich. Prof Wagner will focus on the congress theme of ‘Innovation’, giving us his unique perspective on how evolution drives human creativity....Andreas Wagner: ESPO 2025 keynote speaker
The keynote speaker for ESPO 2025 in Stuttgart is renowned evolutionary biologist and author Professor Andreas Wagner, from Zurich. Prof Wagner will focus on the congress theme of ‘Innovation’, giving us his unique perspective on how evolution drives human creativity....BACO – the early years
The origins of the British Academic Conference in Otolaryngology (BACO) are indelibly intertwined in the mists of time with the foundation of the British Association of Otolaryngology (BAO). For further information on the latter I can only refer the interested...
Advances in diagnosis and management of allergic rhinitis
This article reviews advances in the diagnosis and management of allergic rhinitis. Recent advances in the diagnosis of allergic rhinitis include testing of local immunoglobulin E (IgE), urinary test to diagnose aspirin hypersensitivity and optical rhinometry to assess degree of...
A trial of house dust mite sublingual tablet in children with allergic rhinitis
The house dust mite (HDM) is one of the commonest causative agents in allergic rhinitis (AR), affecting patients across all demographics. Recently, sublingual immunotherapy (SLIT) has been shown in clinical trials and meta-analysis to be effective compared to placebo in...
Biologicals for severe chronic rhinosinusitis with nasal polyps. Any use?
Recent advances and knowledge of inflammatory endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) led to introduction of biological agents such as monoclonal antibodies targeting IgE (omalizumab) and Interleukins (ILs) such as IL4R alpha (dupilumab) and IL5. The European Academy...
